Because the G protein of respiratory syncytial virus (RSV) has a CX3C chemokine motif that has been associated with the ability of RSV G protein to modulate the virus-induced host immune response, we examined whether therapeutic treatment with an anti-RSV G monoclonal antibody (mAb), 131-2G, that blocks the CX3C-associated activity of RSV G protein might decrease the pulmonary inflammatio associated with infection in BALB/c mice. The results show that treatment with mAb 131-2G on day 3 after RSV infection reduces both inflammatio and RSV titer in the lungs. Later administration of anti-RSV G mAb (day 5 after RSV infection) effectively reduced the viral titer but had a minimal effect on pulmonary inflammation This study suggests that an anti-RSV G mAb might be an effective antiviral, either alone or in combination with anti-RSV F protein neutralizing antibodies, for decreasing the virus-induced host response to infection and improve treatment outcome.
young children worldwide, and RSV can cause repeat infections throughout life, with serious complications in elderly persons and immunocompromised patients [1] [2] [3] [4] . To date, there is no safe and effective vaccine available, and treatment options are limited. The protective immune response to RSV infection is primarily directed against the 2 major surface viral proteins, the G (attachment) and the F (fusion) glycoproteins. The RSV F glycoprotein is the most effective viral protein in inducing protective immunity in animal model systems [5, 6] . Consequently, efforts to treat and prevent RSV infection have often focused on anti-RSV F protein antibodies, antiviral drugs that affect the F protein, and live virus-based or F protein-based vaccines. Prophylactic treatment with an anti-RSV F neutralizing monoclonal antibody (mAb), palivizumab, was proven to be effective in preventing serious complications of RSV infection in high-risk infants and young children and is now licensed and regularly used for this purpose [7] . This mAb, however, was not effective in treating active infection, and other treatments for acute RSV infection have proven to be either ineffective or minimally effective [8] . For example, ribavirin, an antiviral drug, is licensed for the treatment of severe RSV infection but has limited efficac and is seldom used except for treatment of infection in immunocompromised patients [9] [10] [11] .
One possible explanation for the ineffectiveness of existing RSV treatments is that the virus-induced host inflammato y response is important to the pathogenesis of disease and that this inflammato y response is only partially responsive to antiviral therapy once infection is established. Consequently, effective treatment may require both anti-inflammato y and antiviral components [12] . A number of studies have suggested that the G protein of RSV plays a substantial role in inducing and modulating the host immune response to infection [13] . Intact RSV G protein expression in the infecting virus is associated with a lower frequency of interferon g (IFN-g)-expressing cells and a higher frequency of interleukin 4 (IL-4)-expressing cells [14] . RSV G protein has also been associated with increased pulmonary eosinophilia after RSV challenge in formalin-inactivated RSV-vaccinated mice [15, 16] , increased pulmonary levels of substance P in RSV-challenged mice [17] , and decreased respiratory rates associated with its administration to mice [18] . Several of these effects of RSV G protein have been attributed to its CX3C chemokine motif. This motif, located between aa 182-186 in the central conserved region of the RSV G protein, is present in all naturally occurring strains of RSV and appears to mimic some activities of the only known cellular CX3C chemokine, fractalkine [14, 19] . Blocking of RSV G protein binding to the CX3C receptor, CX3CR1, inhibits RSV infection, G protein-induced leukocyte migration in vitro [19] , the eosinophilic inflammato y response seen after formalin-inactivated RSV vaccination of mice [20] , and depressed respiratory rates in mice [18] . More recently, we have shown that antibodies in human serum block RSV G protein binding to CX3CR1 and leukocyte migration and that the titer of these antibodies rises after RSV infection; there appears to be some strain specificit to this blocking effect, and the presence of these antibodies may be associated with protection from RSV disease [21] .
Because RSV G protein binding to CX3CR1 is associated with the inflammato y response to RSV, we hypothesized that administration of an anti-RSV G mAb that blocks RSV G pro- tein binding to CX3CR1 may have an anti-inflammato y effect during RSV infection and consequently improve the ability of antiviral treatment to decrease disease severity. In the present study, we examined the effectiveness of treatment with a nonneutralizing anti-RSV G mAb, 131-2G, that blocks G protein binding to CX3CR1, alone or in combination with a neutralizing anti-RSV F mAb. The results show that treatment with anti-RSV G mAb inhibits viral replication and reduces the inflammato y response associated with RSV infection. This anti-inflammato y effect is also present when anti-RSV G antibody is coadministered with anti-RSV F antibody and is greater than that observed after the administration of anti-RSV F antibody alone, suggesting that anti-RSV G antibodies might provide the anti-inflammato y activity needed to improve the effectiveness of treatments for RSV disease.
METHODS

Animals.
Eight-to 10-week old, specifi pathogen-free, female BALB/c mice (Jackson Laboratory) were used in all experiments. Mice were housed in microisolator cages and were fed sterilized water and food ad libitum. All experiments were performed in accordance with the guidelines of the institutional animal care and use committee.
Virus and infection. The A2 strain of RSV was used in all experiments and propagated in Vero cells (ATCC CCL 881) as described elsewhere [22] . Mice were anesthetized by intraperitoneal administration of Avertin (2% 2,2,2-tribromoethanol and 2% tert-amyl alcohol; 180-250 mg/kg) and intranasally challenged with plaque-forming units of RSV in serum- 6 1 ϫ 10 free Dulbecco modifie Eagle medium (DMEM) (50-mL volume). No fewer than 3 mice per treatment were examined per time point.
Antibodies and treatment. On day 3 or 5 after infection, mice were intraperitoneally treated with 150-300 mg of anti-RSV G mAb (131-2G; endotoxin concentration, !5 endotoxin units/mg), control normal mouse immunoglobulin G (IgG) (Pierce), or purifie mouse immunoglobulin G1 (IgG1) isotype antibody (BD Biosciences). For combination antibody experiments, mice were intraperitoneally treated with 300 mg of anti-RSV G mAb (131-2G; endotoxin concentration, !5 endotoxin units/mg) and 150 mg of anti-RSV F mAb (143-6C) or with control normal mouse IgG (Pierce) (150-300 mg/mouse) either alone or in combination with anti-RSV F or anti-RSV G mAb. Endotoxin concentrations were determined using a Limulus amebocyte lysate chromogenic end-point assay, in accordance with the manufacturer's instructions (Hycult Biotechnology). If the endotoxin concentration in the mAb was 15 endotoxin units/mg, then the endotoxin was removed using an endotoxinremoving gel, in accordance with the manufacturer's instructions (Pierce). The anti-RSV F mAb (clone 143-6C) used in these experiments is similar to palivizumab in that both antibodies recognize the same epitope on the F protein and neutralize and inhibit RSV infection [23, 24] .
Quantitation of IFN-g and IL-4. IL-4 and IFN-g levels in cell-free bronchoalveolar lavage (BAL) flui were analyzed using a capture enzyme-linked immunoassay kit, in accordance with the manufacturer's instructions (eBiosciences). Samples were run in duplicate.
Cell collection and analysis. Mice were anesthetized with Avertin and exsanguinated by severing the right brachial artery. BAL leukocytes were harvested by lavaging the lungs 3 times with 1 mL of Dulbecco phosphate-buffered saline (PBS) (Gibco). The procedure used for extracellular staining of BAL cells was modifie for microculture staining as described elsewhere [22] . Brief y, BAL cells were washed in Dulbecco PBS containing 1% bovine serum albumin (Sigma) and then stained (at 4ЊC for 30 min) with an appropriate dilution of fl orescein isothiocyanate-, allophycocyanin-, or phycoerythrin-conjugated anti-CD3 (145-2C11), anti-CD45R/B220 (RA3-6B2), anti-CD8 (Ly-2), anti-neutrophil (PMN) (RB6-8C5), or antiCD11b (M1/70) antibody or with isotype antibody controls (BDBiosciences).
Viral titers. Viral titers in the lungs of RSV-infected mice were determined as described elsewhere [25] . Briefl , lungs were aseptically removed from 3 or 4 mice per group on days 3, 5, 7, or 11 after infection and stored at Ϫ70ЊC until assay. Lungs were weighed, individual lung samples were homogenized in 1 mL of cold and sterile Dulbecco PBS, and 10-fold serial dilutions (in serum-free DMEM) of the lung homogenates were added to confluen Vero cell monolayers in 24-well plates. After adsorption for 2 h at 37ЊC, cell monolayers were overlaid with tissue culture DMEM (Gibco) containing 10% fetal bovine serum (Hyclone), incubated at 37ЊC for 3 or 4 days, and then enumerated by immunostaining with mAb against the G and F proteins (232-1F, 130-6D, and 131-2A, respectively). Statistical analysis. Statistical significanc was determined using the Student t test. Differences with were consid-P ! .05 ered statistically signific nt.
RESULTS
Reduction in pulmonary inflammatio due to early therapeutic treatment with anti-RSV G mAb. mAb 131-2G has been shown to react between aa 1 and 173 [25] , and, since it reacts against both the A and the B strain of RSV [23] , it likely binds within the central conserved region, aa 164-176. To assess the therapeutic effectiveness of mAb 131-2G, BALB/c mice were treated with either a low dose (150 mg) or a high dose (300 mg) of antibody on day 3 after RSV infection, which is before the peak of maximal viral replication and inf ammatory response [26] . Early treatment with either low-dose or high-dose mAb 131-2G was associated with significan reductions in pulmonary leukocyte traffickin ( and , respec-P p .028 P p .013 tively) and in viral titer in the lungs, compared with values for control antibody-treated mice, by day 5 after infection (fi ure 1A and 1D). At the peak of pulmonary inflammation mice treated with high-dose anti-RSV G mAb had a ∼60% reduction in total BAL cells, compared with that in normal IgG-treated mice.
By day 7 after infection, the level of pulmonary infiltratio in low dose-treated mice was comparable to that in control antibody-treated mice. In contrast, at this later time point mice treated with high dose antibody continued to exhibit signifcantly reduced pulmonary cell infiltratio ( ), com-P p .015 pared with that in mice treated with low-dose mAb 131-2G or control antibody, suggesting that mAb 131-2G treatment is associated with decreased pulmonary cell infiltratio in a dosedependent manner.
To determine the alveolar inflammato y cell types affected by mAb 131-2G treatment, the BAL cell subsets were determined at various time points after treatment (table 1). Highdose mAb 131-2G treatment was linked to a marked reduction in CD4
+ and CD11b + cell trafficking and both low-dose and high-dose treatment were associated with modest decreases in CD8 + , DX5 + natural killer, and RB6-8C5 + PMN cells in the BAL cell population on day 5 after infection. By day 7 after infection, both antibody treatments decreased the numbers of all cell subsets examined; however, the greatest reduction was linked to the high-dose mAb 131-2G treatment. The levels of type 1 T-helper (IFN-g) and type 2 T-helper (IL-4) cytokines in the cell-free BAL supernatant were determined by ELISA. mAb 131-2G treatment had little effect on the already low levels of IL-4; however, treatment with both low-dose and high-dose antibody markedly decreased IFN-g levels in cell-free BAL supernatants (figu e 1B and 1C). These finding suggest that anti-RSV G antibody that blocks G protein binding to CX3CR1 inhibits aspects of pulmonary inflammatio associated with RSV infection.
The relationship between reduced pulmonary cell infiltratio and viral titers was examined (figu e 1D). On day 5 after infection, which corresponds to the peak of viral replication in this model [26] , there was a marked decrease ( ) in viral P ! .016 titers in mice treated with low-dose mAb 131-2G, and by day 7 the levels of virus were below the limits of detection. On days ) between mice treated with normal IgG and those treated with P ! .05 anti-RSV protein mAbs. The arrow references the time of treatment. ND, not detectable (levels of virus were below the limit of detection).
5 and 7 after infection, no virus was detected in the lungs of mice treated with 300 mg of mAb 131-2G. The ability of mAb 131-2G to increase viral clearance was unexpected, because this antibody does not have neutralizing activity in vitro. The administration of an IgG1 isotype-matched control antibody in RSV-infected mice did not affect RSV load, BAL cell infiltration or BAL cytokine levels (data not shown). Taken together, these results suggest that dose-dependent decreases in pulmonary cell infiltratio and RSV lung titers are associated with anti-RSV G antibody (mAb 131-2G) treatment.
Effects of late anti-RSV G mAb treatment on pulmonary inflammation
The results for early anti-RSV G antibody treatment suggested that similar treatment might be effective at minimizing the pulmonary inflammato y response associated with RSV infection if given at the peak of RSV infection (day 5 after infection). Mice were treated on day 5 after infection with either 300 mg of mAb 131-2G or control antibody (normal IgG). Similar to day 3 treatment, day 5 treatment signif cantly reduced viral titers in the lungs (∼1 log), compared with those in control mice (fi ure 2D).
Late therapeutic treatment with mAb 131-2G was not associated with an overall reduction in pulmonary cell traffi king (figu e 2A) but was associated with a reduction in selected cells types (ie, CD11b + cells) on day 7 after infection (2 days after treatment), a modest decrease in DX5 + cells on day 7 after infection and at later time points, a slight increase in RB6-8C5 + PMNs and CD4 + cells on day 7 after infection, and a minimal effect on B220 + , CD4 + , and CD8 + cells (table 2) . Late antibody treatment significantl decreased the levels of IFN-g in BAL fluid compared with control treatment with normal IgG on day 7 after infection (figu e 2B). There was no substantial difference in the magnitude of IL-4 expression between treatment with mAb 131-2G and normal IgG (fi ure 2C).
Effective reduction in RSV infection and associated inf ammation after combination anti-RSV G and anti-RSV F mAb treatment. We have previously shown that treatment with the anti-RSV F neutralizing mAb 143-6C, which recognizes the same antigenic site (site A) as humanized anti-RSV F mAb (palivizumab), was not effective at reducing pulmonary infl mmation when given before (prophylactic) or after (treatment) RSV infection [26] . Because the anti-RSV G mAb 131-2G given alone decreased RSV-induced pulmonary inflammation we examined whether combining it with the anti-RSV neutralizing mAb 143-6C might also result in decreased pulmonary inflam mation. Treatment on day 3 after infection with anti-RSV G mAb ( ) or with anti-RSV G and anti-RSV F mAb P p .015 ( ) was associated with a decrease in pulmonary inflam P ! .005 matory cells, compared with treatment with anti-RSV F antibody or with normal IgG, on day 5 after infection (fi ure 3A). By day 7 after infection, the numbers of BAL cells were similar for all treatments.
Two days after antibody treatment, the numbers for all leukocyte subsets in anti-RSV G-treated mice were decreased, compared with those in anti-RSV F-treated or normal IgGtreated mice (table 3) . In anti-RSV G-treated mice, a marked decrease in levels of CD8 + cells, CD4 + cells, DX5 + cells, and 
RB6-8C5
+ PMNs and a modest decrease in levels of B220 + and CD11b + cells was observed until day 7 after infection. Consistent with the finding of our previous studies, early treatment with anti-RSV F mAb alone was associated with a pronounced reduction in the level of CD8 + cells and some reduction in levels of CD4 + , B220 + , and DX5 + cells by day 5 after infection [26] .
Similar to anti-RSV G mAb treatment alone, combination anti-RSV G and anti-RSV F treatment led to a marked decrease in all leukocyte subsets by day 5 after infection. By day 7 after infection, levels of CD8 + , B220 + , DX5 + , and RB6-8C5 + cells remained reduced, with only a slight increase in levels of CD4 + and CD11b + cells. As expected, administration of anti-RSV G or anti-RSV F antibodies alone or in combination increased clearance of virus from the lungs of treated mice (figu e 3C). There was a significan decrease in IFN-g levels in the BAL flui of mice from all treatment groups and minimal IL-4 production (fi ure 3B). This decrease in IFN-g levels is likely associated with either a reduction in levels of inflammato y cells or a decrease in RSV load.
DISCUSSION
Specifi therapeutic options for RSV infections are limited, and currently only the antiviral agent ribavirin is approved for this indication. Our data suggest that an anti-RSV G mAb such as 131-2G, alone or in combination with an antiviral drug or an anti-RSV F neutralizing mAb (eg, palivizumab), might make an effective RSV-specifi treatment. mAb 131-2G appears to have 2 actions that could contribute to effective RSV treatment, that is, a decrease in the pulmonary inflammato y response to infection and a decrease in viral titer in the lungs. We hypothesized that this mAb would have an anti-inflammato y effect, which might address the possibility that effective treatment for an ongoing infection requires anti-inflammato y as well as antiviral treatment. We did not expect that this nonneutralizing mAb would also have substantial antiviral activity.
The anti-inflammato y effect of mAb 131-2G likely relates, at least in part, to its ability to block RSV G protein binding to CX3CR1 through its CX3C chemokine motif [19] . We have previously shown that RSV G glycoprotein binding to CX3CR1 enhances RSV infection of cells, contributes to enhanced disease after formalin-inactivated RSV immunization, and contributes to RSV G protein-associated reduction in respiratory rates. Blocking RSV G protein binding to CX3CR1 inhibits RSV infection and RSV G protein-induced leukocyte migration. Furthermore, treatment with anti-RSV G or anti-CX3CR1 antibodies dramatically reduced the effect of RSV G protein on respiratory rates in mice [18] . We have also demonstrated that blocking the RSV G protein CX3C-CX3CR1 interaction by means of anti-CX3CR1 antibody before RSV challenge of mice vaccinated with formalin-inactivated RSV reduced or eliminated the eosinophilic inflammato y response [20] .
The tachykinin neuropeptide substance P (SP) contributes to RSV G protein-associated inflammatio in the mouse model [13, 17] . SP is produced by afferent neurons and a variety of immune cells, and its expression has been shown to affect vasodilation and immune cell recruitment to the site of infection [27] [28] [29] [30] [31] [32] [33] [34] . RSV infection of BALB/c mice is associated with high pulmonary SP levels, and these increased levels of SP appear to exacerbate pulmonary inflammatio and are associated with altered natural killer cell responses [17, 20] , suggesting that SP is an important contributor to the pathogenesis of RSV infection. We have also shown that administration of anti-SP antibodies in combination with anti-RSV F antibodies to BALB/ c mice after RSV challenge decreased the inflammato y response to infection [26] . Data from experiments investigating the association between decreased respiratory rate and RSV G protein suggest that the protein induces SP through binding to CX3CR1 and that SP expression contributes to lower respiratory rates; in these experiments, administration of antibodies to RSV G protein, CX3CR1, and SP had similar effects, inhibiting the RSV G protein-associated decrease in respiratory rate and induction of SP [18] .
Combination administration of mAb 131-2G with the anti-RSV F neutralizing mAb 143-6C, which reacts at the same antigenic site (site A) as the anti-RSV F mAb palivizumab [23] , demonstrated that the decrease in pulmonary inflammatio was not solely the result of decreased viral replication. Administration of this antibody is highly effective in decreasing viral titer, and we suspect that the addition of mAb 131-2G does not enhance this clearance. Our data do show, however, that this mAb combination is consistently associated with a reduction in levels of pulmonary inflammato y cells and cytokine production.
Unexpectedly, anti-RSV G mAb treatment was consistently associated with reduced viral titers regardless of the time of administration. mAb 131-2G in the presence or absence of complement does not neutralize RSV in vitro (authors' unpublished data). There are several mechanisms that nonneutralizing antibodies use to facilitate viral clearance in vivo, including complement-dependent or antibody-mediated cellular cytotoxicity (ADCC). The exact mechanism used by mAb 131-2G in vivo is not fully understood; however, recent investigations have indicated that it may involve an ADCC mechanism [35] .
The results reported here indicate that the anti-RSV G mAb 131-2G serves 2 functions in the treatment of RSV infection, down-regulating aspects of the virus-induced host inf ammatory response to infection that may contribute to the pathogenesis of disease (possibly by blocking G protein binding to CX3CR1) and facilitating viral clearance. Anti-RSV G antibodies alone or in combination with antiviral drugs or with other neutralizing antibodies may make it possible to develop highly effective therapy for ongoing RSV infections.
